26 citations
,
February 2009 in “Drug Development Research” This article reviews the potential neuroprotective effects of 17α‐estradiol in neurodegenerative diseases and highlights its possibly lower toxicity compared to more feminizing hormones, but it reports no new clinical findings.
6 citations
,
July 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review evaluates the use of 5α-reductase inhibitors in feminising hormone therapy, finding their additive feminising benefits unclear due to their specific action on testosterone conversion, with concerns highlighted regarding limited supporting evidence and safety signals, particularly for psychiatric and sexual effects.
This review concluded that 5α-reductase inhibitors like finasteride and dutasteride offer limited additional feminising effects in hormone therapy for transfeminine individuals, with the clearest use being androgenetic alopecia treatment; more research is needed for other potential benefits.
34 citations
,
April 2023 in “Climacteric” This review discusses the long-term effects of gender affirming hormone therapy and reports no new clinical findings, recommending a shared decision-making approach to balance benefits and risks for transgender individuals.
October 2024 in “Journal of the Endocrine Society” This study found that feminizing hormone therapy increased GFR in transgender individuals assigned male at birth, suggesting an effect of sex hormones on kidney hemodynamics, while masculinizing therapy showed a slight, nonsignificant decrease in GFR.